Cellectricon will present a novel phenotypic assay at World Pharma Congress 2013

A fresh approach to developing chronic pain therapeutics

Cellectricon will present a novel phenotypic assay at World Pharma Congress 2013, Tues 4^th June, 5pm

 

Molndal, Sweden – 29 May 2013 – Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be attending the 12^th annual World Pharma Congress, 4 – 6 June (Philadelphia, PA). At the event, Cellectricon’s Head of Discovery Services, Dr Paul Karila, will host a presentation describing a novel phenotypic assay for the identification of therapeutic compounds for chronic pain. The talk, entitled ‘Development of a Phenotypic Pain Assay for Identification of Modulators of Excitability in Native Sensory Neurons’, will take place on Tues 4^th June, 5pm, as part of the ‘Targeting Pain with Novel Therapeutics’ program.

 

This exciting new assay is based on the Cellaxess^® technology platform, and uses electric field stimulation of primary DRG neuronal cultures to allow compound identification during early stages of the project lifecycle. As such, Dr Karila will explain how the approach can add significant value to the overall decision-making process of drug development, saving valuable time and cost.

 

Dr Paul Karila is Chairperson for the ‘Targeting Pain with Novel Therapeutics’ program, and will be on-hand throughout the day to answer any questions on Cellectricon’s services and technology. Alternatively, for more information on Cellectricon, please visit www.cellectricon.com

 

About Cellectricon

 

Cellectricon provides state-of-the-art discovery services and enabling technologies to accelerate drug discovery and cell-based research. Our compound profiling services in excitable cells and native tissue provide researchers with decision-making insight into the science of cytoskeletal disturbances, particularly focusing on chronic pain